Eli Lilly Archives -

News/ News/ News/ Patients/ Sales and Marketing

Bayer tops pharma rankings for diversity, inclusivity

Phil Taylor alva, Astellas, Bayer, diversity and inclusion, Eli Lilly, Gilead Sciences, pharma reputation, Sanofi, Teva 0 Comment

The largest pharma companies have all set themselves ambitious targets in recent years to improve representation for women

Bayer tops pharma rankings for diversity, inclusivity

https://pharmaphorum.com/news/bayer-tops-pharma-rankings-for-diversity-inclusivity/

News/ News/ R&D

Gilead snaps up MiroBio and its checkpoint agonists for $405m

Phil Taylor AnaptysBio, Eli Lilly, Gilead Sciences, Immunology and inflammation, M&A, MiroBio 0 Comment

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a

Gilead snaps up MiroBio and its checkpoint agonists for $405m

https://pharmaphorum.com/news/gilead-snaps-up-mirobio-and-its-checkpoint-agonists-for-405m/

News/ News/ R&D

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Phil Taylor China, Eli Lilly, financing, Genfleet Therapeutics, GlaxoSmithKline, Immunology and inflammation, Rigel Pharmaceuticals, RIPK1, Sanofi, Sironax 0 Comment

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire

Chinese biotech Sironax raises $200m for RIPK1 pipeline

https://pharmaphorum.com/news/chinese-biotech-sironax-raises-200m-for-ripk1-pipeline/

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

Phil Taylor breast cancer, Eli Lilly, HEOR, NHS, NICE, Oncology, Verzenio 0 Comment

Thousands more people with breast cancer in England look set to be eligible for routine treatment with Eli

Lilly’s Verzenios gets NICE blessing for early-stage breast cancer

https://pharmaphorum.com/news/lillys-verzenios-gets-nice-blessing-for-early-stage-breast-cancer/

Digital/ News/ News

Lilly partners with Sidekick in digital health alliance

Phil Taylor breast cancer, digital, digital health, digital therapeutics, Eli Lilly, Oncology, partnering, Sidekick Health 0 Comment

A personalised, treatment plan for patients with breast cancer is the first digital health product to emerge from

Lilly partners with Sidekick in digital health alliance

https://pharmaphorum.com/news/lilly-partners-with-sidekick-in-digital-health-alliance/

Market Access/ News/ News/ News/ Sales and Marketing

Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit

Phil Taylor alopecia, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Olumiant, Pfizer 0 Comment

Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia

Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit

https://pharmaphorum.com/news/lillys-olumiant-okayed-in-alopecia-with-pfizer-concert-in-hot-pursuit/

News/ News/ Sales and Marketing

Sanofi’s plans for OTC Cialis hit a snag in US

Phil Taylor cialis, Eli Lilly, erectile dysfunction, OTC, Pfizer, Sanofi, Viagra 0 Comment

It has been eight years since Sanofi licensed rights to an over-the-counter version of erectile dysfunction (ED) drug

Sanofi’s plans for OTC Cialis hit a snag in US

https://pharmaphorum.com/news/sanofis-plans-for-otc-cialis-hit-a-snag-in-us/

News/ News/ Sales and Marketing

Lilly sets aside $2.1bn for domestic investments

Phil Taylor Eli Lilly, Indiana, investment, manufacturing 0 Comment

Eli Lilly’s home state of Indiana is set to benefit from a massive $2.1 billion investment by the

Lilly sets aside $2.1bn for domestic investments

https://pharmaphorum.com/news/lilly-sets-aside-2-1bn-for-domestic-investments/

Trending

Eli Lilly

Login